Conference Call with Torrent Pharmaceuticals Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Torrent Pharmaceuticals declares Q3FY22 result: Revenue at Rs. 2,108 crores up by 6% Gross margins: 70%; EBITDA margins: 28%. EBITDA at Rs. 585 crores was down by 5%. Profit before tax at Rs. 357 crores was flat. Net profit after tax at Rs. 249 crores was down by 16%. Commenting on the Q3 results, Samir Mehta, Chairman, said “Due to the prolonged delays in reinspection of our US facilities on account of the pandemic, coupled with higher than anticipated pricing pressure, our US business has been adversely affected during this quarter. We remain hopeful of our prospects in the US market as soon as the facilities are reinspected. We have initiated cost optimisation measures which should help us get back on track with respect to margins in the upcoming quarters. Our India business continues to be on a strong footing delivering significantly higher than market growth during the quarter.” Result PDF